Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Selpercatinib

FDA-approved product (capsule, oral), marketed as Retevmo.

Registered studies
42
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Selpercatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Non-small cell lung carcinoma
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Selpercatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Selpercatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

    NCT05089019 · start 2021-10-29

    Registered record
    Registry ID
    NCT05089019
    Conditions
    Healthy
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-29
    Completion
    2022-07-19
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelpercatinib
    PhasePhase 1
    Registry statusCompleted

  • Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

    NCT04320888 · start 2021-05-03

    Registered record
    Registry ID
    NCT04320888
    Conditions
    Hematopoietic and Lymphatic System Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Lymphoma; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent WHO Grade 2 Glioma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Lymphoma; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory
    Interventions
    Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Radionuclide Imaging; Selpercatinib; X-Ray Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-05-03
    Completion
    2027-06-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphatic System Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma +28 more
    InterventionComputed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Radionuclide Imaging +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Improving Public Cancer Care by Implementing Precision Medicine in Norway

    NCT04817956 · start 2021-04-01

    Registered record
    Registry ID
    NCT04817956
    Conditions
    Cancer Metastatic
    Interventions
    Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2045-04-30
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer Metastatic
    InterventionAtezolizumab
    PhasePhase 2
    Registry statusRecruiting

  • A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

    NCT04782076 · start 2021-03-05

    Registered record
    Registry ID
    NCT04782076
    Conditions
    Healthy
    Interventions
    Dabigatran; Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-05
    Completion
    2021-05-17
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDabigatran; Selpercatinib
    PhasePhase 1
    Registry statusCompleted

  • Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

    NCT04759911 · start 2021-02-26

    Registered record
    Registry ID
    NCT04759911
    Conditions
    Malignant Thyroid Gland Neoplasm; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Anaplastic Carcinoma; Thyroid Gland Medullary Carcinoma; Thyroid Gland Papillary Carcinoma; Thyroid Gland Squamous Cell Carcinoma
    Interventions
    Quality-of-Life Assessment; Questionnaire Administration; Selpercatinib; Therapeutic Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-02-26
    Completion
    2027-11-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Thyroid Gland Neoplasm; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Thyroid Gland Anaplastic Carcinoma +3 more
    InterventionQuality-of-Life Assessment; Questionnaire Administration; Selpercatinib; Therapeutic Conventional Surgery
    PhasePhase 2
    Registry statusActive not recruiting

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

    NCT04268550 · start 2020-04-08

    Registered record
    Registry ID
    NCT04268550
    Conditions
    Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-04-08
    Completion
    2026-12-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionSelpercatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

    NCT04280081 · start 2020-03-16

    Registered record
    Registry ID
    NCT04280081
    Conditions
    Solid Tumor; Medullary Thyroid Cancer
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-03-16
    Completion
    2028-11
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Medullary Thyroid Cancer
    InterventionSelpercatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    NCT04194944 · start 2020-02-17

    Registered record
    Registry ID
    NCT04194944
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Selpercatinib; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-02-17
    Completion
    2030-06
    Enrolment
    261

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSelpercatinib; Carboplatin; Cisplatin; Pemetrexed +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

    NCT04211337 · start 2020-02-11

    Registered record
    Registry ID
    NCT04211337
    Conditions
    Medullary Thyroid Cancer
    Interventions
    Selpercatinib; Cabozantinib; Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-02-11
    Completion
    2027-11
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Cancer
    InterventionSelpercatinib; Cabozantinib; Vandetanib
    PhasePhase 3
    Registry statusActive not recruiting

  • A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

    NCT06195228 · start 2020-01-01

    Registered record
    Registry ID
    NCT06195228
    Conditions
    Advanced Thyroid Cancer Patients Who Received Target Therapy
    Interventions
    dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy; pralsetinib or selpercatinib with or without anti-PD-1 antibdoy; anlotinib or anlotinib plus anti-PD-1 antibody; lenvatinib plus anti-PD-1 antibody; Other Targets: precise treatment based on the target
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2020-01-01
    Completion
    2028-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Thyroid Cancer Patients Who Received Target Therapy
    Interventiondabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy; pralsetinib or selpercatinib with or without anti-PD-1 antibdoy; anlotinib or anlotinib plus anti-PD-1 antibody +2 more
    PhasePhase 4
    Registry statusRecruiting

  • Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

    NCT05338502 · start 2019-07-08

    Registered record
    Registry ID
    NCT05338502
    Conditions
    Healthy
    Interventions
    Selpercatinib; Ranitidine; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-07-08
    Completion
    2019-09-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelpercatinib; Ranitidine; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

    NCT03944772 · start 2019-06-25

    Registered record
    Registry ID
    NCT03944772
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Osimertinib; Savolitinib; Gefitinib; Necitumumab; Durvalumab; Carboplatin; Pemetrexed; Alectinib; Selpercatinib; Selumetinib; Etoposide; Cisplatin; Datopotamab deruxtecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-06-25
    Completion
    2025-05-06
    Enrolment
    247

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionOsimertinib; Savolitinib; Gefitinib; Necitumumab +9 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

    NCT03899792 · start 2019-06-13

    Registered record
    Registry ID
    NCT03899792
    Conditions
    Medullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Cancer; Soft Tissue Sarcoma
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2019-06-13
    Completion
    2029-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Cancer +1 more
    InterventionSelpercatinib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

    NCT05630274 · start 2019-04-16

    Registered record
    Registry ID
    NCT05630274
    Conditions
    Healthy
    Interventions
    Selpercatinib; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-16
    Completion
    2019-06-21
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelpercatinib; Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusCompleted